KAM
AVDL

Kazazian Asset Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Kazazian Asset Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-106,120
Closed -$831K – 50
2025
Q1 		$831K Buy
106,120
+94,120
+784% +$788K 0.68% 22
2024
Q4 		$126K Buy
+12,000
New +$146K 0.1% 57

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kazazian Asset Management's AVDL Position: Q2 2025 in Review

Kazazian Asset Management sold out of Avadel Pharmaceuticals (AVDL) in Q2 2025, closing a stake of 106,120 shares — an estimated $831K sold.

Kazazian Asset Management first reported a position in AVDL in Q4 2024 and held it in 2 quarters. The position peaked at $831K in Q1 2025. 173 funds tracked by Wall St. Rank hold AVDL as of Q2 2025.

  • Kazazian Asset Management reported no remaining Avadel Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Kazazian Asset Management sold 106,120 Avadel Pharmaceuticals shares in Q2 2025, an estimated $831K.
  • Kazazian Asset Management first reported a position in Avadel Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Kazazian Asset Management's Avadel Pharmaceuticals position peaked at $831K in Q1 2025.
  • 173 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2025.

Based on Kazazian Asset Management's 13F filing for Q2 2025, filed 11 Aug 2025.